Abstract: Provided are compositions and methods for determining an imprinting status of a gene subject to parent-of-origin, monoalleleic expression in a subject, and for using the information derived therefrom to detect a presence of and/or a susceptibility to a medical condition associated with monoallelic expression in a subject, predict a susceptibility to future development of a medical condition prior to the onset of any symptoms, monitor the development of such a medical condition and/or the effectiveness of a treatment, and for treating such a medical condition. In some embodiments, a composition for use in the disclosed methods is nucleic acid array, which in some embodiments can include one or more interrogatable nucleotide molecules, wherein the interrogatable nucleotide molecules are designed to allow identification of the DNA methylation status of one or more imprint control regions (ICRs) that regulate one or more genes subject to monoalleleic expression in subjects.

Abstract: Methods for identifying imprinted genes. In some embodiments, the methods comprise (a) providing a first data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known to be imprinted in the subject; (b) providing a second data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known not to be imprinted in the subject; (c) identifying one or more features that by themselves or in combination are differentially present or absent from the first data set as compared to the second data set; and (d) applying the one or more features to a test data set comprising a plurality of genomic DNA sequences which correspond to one or more genes for which the imprinting status is unknown to thereby identify an imprinted gene in a subject.

Abstract: The present invention relates, in general, to cancer prognosis and, in particular, to a method of assessing the prognosis of a patent using the M6P/IGF-II receptor.

Abstract: The present invention relates, in general, to a tumor suppressor and, in particular, to the mannose 6-phosphate/insulin-like growth factor-II (M6P/IGF-II) receptor and to diagnostic and therapeutic approaches based on same.